Phase 2 Study of CAN008 in Newly Diagnosed GBM

• Status: Recruiting
• Trial end date: 2024-08-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, randomized, double-blind, placebo-controlled Phase 2 study whose objectives are to evaluate the clinical efficacy and safety of CAN008 plus TMZ during and after radiation therapy in newly-diagnosed subjects with glioblastoma who have undergone surgical excision.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CANbridge Life Sciences Ltd.

Criteria

Inclusion Criteria:

• Age 18 to 70.

• Newly diagnosed glioblastoma.

• Tumor excision rate ≥80%.

• Karnofsky performance score ≥70.

Exclusion Criteria:

• Medical history of brain radiation therapy or electric field treatment of tumor.

• Primary infratentorial glioblastoma, multifocal glioma (≥ 2), or leptomeningeal metastasis.

• Any malignant tumor (excluding WHO grade I-II low-grade astrocytomas, basal cell carcinoma, and carcinoma in situ).

• Receiving high-dose hormone therapy.